ENSYSCE BIOSCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-30
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.30%.
- ENSYSCE BIOSCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was -0.60%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | -0.30% 10-K · filed 2026-03-30 |
| 2024-12-31 | -0.60% 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |